HealiusASX:HLS +1.39%53 FCF Yield % is 47.43 as of Jun. 27, 2026, which is 239% above its 10-year median of 13.99. GuruFocus rates ASX:HLS with a GF Score™ of 53/100 and a GF Value™ of A$1.01 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Healius ranks better than 99.07% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Healius's Trailing 12-Month Free Cash Flow is A$126 Mil, and Market Cap is A$265 Mil. Therefore, Healius's FCF Yield % for today is 47.43%.
The historical rank and industry rank for Healius's FCF Yield % or its related term are showing as below:
ASX:HLS'
s FCF Yield % Range Over the Past 10 Years
Min: -0.3 Med: 13.99 Max: 93.14
Current: 47.43
During the past 13 years, the highest FCF Yield % of Healius was 93.14%. The lowest was -0.30%. And the median was 13.99%.
ASX:HLS's FCF Yield % is ranked better than 99.07% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.41
vs ASX:HLS: 47.43
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Healius FCF Yield % Related Terms
Healius FCF Yield % Historical Data
* Premium members only.
The historical data trend for Healius's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Healius's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healius FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Healius's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Healius's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healius (ASX:HLS) has a FCF Yield % of 47.43 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Healius and its competitors. This is 239% above median its historical median of 13.99. According to the industry distribution chart, Healius ranks #2 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 0.90000000000001%.
Is Healius' FCF Yield % too high?
Healius' current FCF Yield % of 47.43 is 239% above median its 10-year median of 13.99. Based on the distribution chart, Healius ranks #2 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Healius has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #2 out of 215 companies for FCF Yield %. This places Healius in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Healius and its competitors. Healius's current FCF Yield % is 47.43, which is 239% above median its own 10-year median of 13.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.01, compared to a current price of A$0.37 — trading 63.9% below its estimated fair value. The current FCF Yield % is 47.43, which is 239% above median its 10-year median of 13.99. Healius' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Healius (ASX:HLS), the current FCF Yield % is 47.43 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healius (ASX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, Healius stock appears to be undervalued.
The current stock price of A$0.37 is trading 63.9% below its estimated GF Value™ of A$1.01.
GuruFocus considers Healius to be Possible Value Trap.
Key valuation signals for ASX:HLS:
FCF Yield %: 47.43 (239% above median its 10-year median of 13.99)
GF Value™: A$1.01 vs. price of A$0.37 (63.9% below fair value)
No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
53GF Score
Get the complete analysis for ASX:HLS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HLS has been successfully added to your 
